These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death. Huang YH; Huang SW; Hsu YF; Ou G; Huang WJ; Hsu MJ Sci Rep; 2015 Oct; 5():15900. PubMed ID: 26510776 [TBL] [Abstract][Full Text] [Related]
4. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225 [TBL] [Abstract][Full Text] [Related]
5. A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade. Yen CS; Choy CS; Huang WJ; Huang SW; Lai PY; Yu MC; Shiue C; Hsu YF; Hsu MJ Front Pharmacol; 2018; 9():167. PubMed ID: 29545751 [TBL] [Abstract][Full Text] [Related]
6. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089 [TBL] [Abstract][Full Text] [Related]
7. WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade. Huang SW; Yang HY; Huang WJ; Chen WC; Yu MC; Wang SW; Hsu YF; Hsu MJ Front Oncol; 2019; 9():1188. PubMed ID: 31781495 [No Abstract] [Full Text] [Related]
8. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer. Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828 [TBL] [Abstract][Full Text] [Related]
10. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways. Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T Life Sci; 2020 May; 248():117469. PubMed ID: 32109485 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy. Zhu S; Zhu W; Zhao K; Yu J; Lu W; Zhou R; Fan S; Kong W; Yang F; Shan P Cell Commun Signal; 2024 Jul; 22(1):361. PubMed ID: 39010083 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011 [TBL] [Abstract][Full Text] [Related]
13. Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1‑survivin downregulation at the late phase of treatment. Wang SC; Wang ST; Liu HT; Wang XY; Wu SC; Chen LC; Liu YW Oncol Rep; 2017 Sep; 38(3):1587-1596. PubMed ID: 28713892 [TBL] [Abstract][Full Text] [Related]
14. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095 [TBL] [Abstract][Full Text] [Related]
15. WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-inflammatory properties via MKP-1 in LPS-stimulated RAW264.7 macrophages. Chen WC; Yen CS; Huang WJ; Hsu YF; Ou G; Hsu MJ Br J Pharmacol; 2015 Apr; 172(7):1894-908. PubMed ID: 25521622 [TBL] [Abstract][Full Text] [Related]
16. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia. Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203 [TBL] [Abstract][Full Text] [Related]
17. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status. Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271 [TBL] [Abstract][Full Text] [Related]
18. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359 [TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997 [TBL] [Abstract][Full Text] [Related]
20. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]